FranceFrance

France Biotech calls for stimulus plan

25.02.2009

France’s biotech industry association has called on the country’s government to revise its decision to cut the OSEO budget by 50% (EUR320m). The tax-paid innovation agency supports small and medium-sized companies. In spite of French President Nicolas Sarkozy's reassurances on January 22nd, the French government has halved its support for innovative start-up companies for 2009. France Biotech argued that the industry currently already has access to too little funding. According to the organisation, investments in French biotechs had already dropped nearly 80% between 2007 and 2008 (down from EUR694m to EUR143m) In addition, says the association, venture capital investments in private companies fell by 27% to EUR132m.
France Biotech Chairman Philippe Pouletty said that "in order to underpin the optimism of our entrepreneurs, we must adopt an aggressive stimulus plan for young, innovative companies." Pouletty has therefore asked the government to reverse the decision and return OSEO’s funding to last year's level, and says that amount should be tripled in 2010. The association has also called on the government to extend the fiscal status of so-called "young innovative companies". Currently, research-oriented SMEs get tax exemptions for the first 8 years after being founded. France Biotech wants to extend that period to 15 years. The organisation also asked for a reform of the French credit law in order to distribute research tax credits more equitably between SMEs and multinationals, and wants 50% of the government's Strategic Investment Fund (FSI) to be given to innovative French SMEs to enable them to acquire undervalued foreign companies and technologies.

FranceFrance

19.08.2011

Marcy l’Etoile – French in vitro diagnostics group Biomérieux S.A. informed the markets that it has acquired Argene, a French company specialising in molecular diagnostics for immuno­compromised patients. Biomérieux said it was...

FranceFrance

17.08.2011

Paris – A team consisting of French scientists and biotech start-up Epixis SA has developed a novel hepatitis C vaccine based on retrovirus-derived virus-like particles (VLPs) pseudotyped with the heterologous viral envelope...

FranceFrance

10.08.2011

Neuilly/New York - Les Laboratoires Servier and Intercept Pharmaceuticals join forces for the development of diabetes drugs. France’s largest independent pharmaceutical company and the US biotech entered into a worldwide ex-U.S....

FranceFrance

20.07.2011

Paris/New Haven - Sanofi pays a $9m milestone payment to Rib-X Pharmaceuticals, Inc. The French pharmaceutical company recently signed worldwide research collaboration and option for license for novel classes of antibiotics...

FranceFrance

12.07.2011

French drug maker Sanofi SA announced mixed results of a late-stage trial of multiple sclerosis drug Lemtrada. The two-year study CARE-MS I is the first of two randomised, Phase 3 clinical trials comparing Sanofi's alemtuzumab to...

FranceFrance

05.07.2011

French Biotech BioAlliance Pharma S.A. has announced plans to raise up toEUR 16.6 million through the sale 3.4 million shares at EUR 4.90 in a rightsissue. The price is a 20% discount to BioAlliance's closing price of EUR6.10...

FranceFrance

14.06.2011

Paris – Pulmonary arterial hypertension (PAH), a severe disease of the arterial blood vessels in the lungs, leads to chronically elevated pulmonary artery pressure and remodelling of the small pulmonary arteries (SMPs) as a...

Displaying results 21 to 30 out of 268

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-france/browse/2/article/france-biotech-calls-for-stimulus-plan.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014


Current issue

All issues

Product of the week

Products